Used primarily in the treatment of autoimmune neurological disorders, particularly neuromyelitis optica spectrum disorder (NMOSD). It targets CD19-positive B cells, leading to their rapid and sustained depletion, which helps prevent immune-mediated damage to the central nervous system. The antibody is especially effective in patients who are aquaporin-4 antibody positive, reducing the risk of relapses and disease progression. Its application allows for a more targeted immunosuppressive approach with a favorable safety profile compared to broad immunosuppressants.